This study published in the journal Tumor Biology, included 124 breast cancer patients with known TNM classification and known values of the well-established breast cancer biomarker CA 15-3. Additionally, 53 healthy individuals were also included in the study, where serum samples were analyzed with the AroCell TK 210 ELISA test, which measures TK1 protein levels. Results demonstrated that the TK 210 ELISA test showed significantly higher sensitivity compared to the TK1 activity test with serum samples from breast cancer patients, particularly with patients in early stages of disease.
“We are pleased and proud to announce the results of our TK 210 ELISA test in this breast cancer study” states Jan Stålemark, AroCell CEO. “Furthermore, this study established that combinational approach of TK 210 ELISA test with CA 15-3 significantly increased the diagnostic sensitivity. These fundamental results are proof that our CE-marked TK 210 ELISA test works in clinical application and can provide important information to oncologists during the course of treatment. These results are important for the continued clinical validation of our test to achieve broad clinical acceptance”.
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell is listed at AktieTorget (AROC) and has about 2 800 shareholders.